Skip to main content

Convenience Wholesaler with 1,200-Store Network in GA, NC, SC, and AL Has Completely Pre-Sold its Initial Shipment of 15 TAAT™ Master Cases Before it Arrives

PSD is a division of Forte International Spirits Direct Distributing, which carries regional specialty brands of liquor and liqueur such as Jaan, Five O’Clock, Zapata, and Tennessee Crown. Operating on a direct-to-store delivery (“DSD”) basis, PSD carries a variety of convenience category products to include beverages, snacks, and specialty lifestyle goods. PSD distributes to approximately 1,200 retail stores including 800 convenience stores as well as liquor stores and independent chains of “cash-and-carry” markets, many of which already carry tobacco products. Approximately 90% of PSD’s accounts are located in the state of Georgia, though it also services retailers in North Carolina, South Carolina, and Alabama. Read More

from Financial Post https://ift.tt/3vXGNlt

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be